{"id":"placebo-zns","safety":{"commonSideEffects":[{"rate":"~15-20%","effect":"Somnolence"},{"rate":"~10-15%","effect":"Ataxia"},{"rate":"~10-15%","effect":"Dizziness"},{"rate":"~5-10%","effect":"Anorexia / weight loss"},{"rate":"~5-10%","effect":"Cognitive impairment"},{"rate":"~1-4%","effect":"Nephrolithiasis"},{"rate":"~1-2%","effect":"Hyperthermia (especially in children)"}]},"_chembl":{"chemblId":"CHEMBL750","moleculeType":"Small molecule","molecularWeight":"212.23"},"_fixedAt":"2026-03-30T12:50:49.248489","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zonisamide inhibits voltage-gated sodium and T-type calcium channels, reducing repetitive neuronal firing and stabilizing neuronal membranes. It also has carbonic anhydrase inhibitory activity and may enhance GABAergic neurotransmission, contributing to its anticonvulsant effects.","oneSentence":"Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:03.549Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive therapy for partial seizures in epilepsy"},{"name":"Infantile spasms (West syndrome)"}]},"_fixedFields":["pubmed(16)"],"trialDetails":[{"nctId":"NCT04774250","phase":"PHASE2","title":"Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2021-11-10","conditions":"Hearing Loss, Noise-Induced","enrollment":3},{"nctId":"NCT04768569","phase":"PHASE2","title":"Noise-Induced Hearing Loss-Acute Exposure Treatment","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2021-10-04","conditions":"Hearing Loss, Noise-Induced","enrollment":24},{"nctId":"NCT04182399","phase":"NA","title":"Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-04-01","conditions":"Parkinson Disease","enrollment":69},{"nctId":"NCT03275922","phase":"PHASE3","title":"Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2017-11-27","conditions":"Migraine","enrollment":374},{"nctId":"NCT01546688","phase":"PHASE4","title":"A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures","status":"TERMINATED","sponsor":"Eisai Limited","startDate":"2008-11","conditions":"Epilepsy","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"recentPublications":[{"date":"2024 Apr","pmid":"38376645","title":"Role of zonisamide in advanced Parkinson's disease: a randomized placebo-controlled study.","journal":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"date":"2023 Sep 6","pmid":"37674206","title":"Efficacy evaluation of a commercially available MCT enriched therapeutic diet on dogs with idiopathic epilepsy treated with zonisamide: a prospective, randomized, double-blinded, placebo-controlled, crossover dietary preliminary study.","journal":"BMC veterinary research"},{"date":"2022 Oct","pmid":"36286602","title":"A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension.","journal":"Headache"},{"date":"2016 Nov 15","pmid":"27568900","title":"Pharmacokinetics of a Novel Zolpidem Nasal Spray for Rapid Management of Insomnia: First Trial in Humans.","journal":"Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine"},{"date":"2012 Nov","pmid":"22902288","title":"The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison.","journal":"Seizure"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"phase_3","status":"active","brandName":"Placebo ZNS","genericName":"Placebo ZNS","companyName":"Impax Laboratories, LLC","companyId":"impax-laboratories-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade. Used for Adjunctive therapy for partial seizures in epilepsy, Infantile spasms (West syndrome).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}